Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wu, Cho Kai ^a,b   Su, Mao Yuan ^c   Lee, Jen Kuang ^a   Chiang, Fu Tien ^a   Hwang, Juey Jen ^a   Lin, Jiunn Lee ^a   Chen, Jin Jer ^d,e   Liu, Fu Tong ^e   Tsai, Chia Ti ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GALECTIN 3;

AGED; ANIMAL; BLOOD; CARDIAC MUSCLE; CELL LINE; DIAGNOSTIC IMAGING; DIASTOLE; DISEASE MODEL; DOG; ECHOGRAPHY; FEMALE; FIBROSIS; HEART; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PRESSURE; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

AGED; ANIMALS; CELL LINE; CONTRAST MEDIA; DIASTOLE; DISEASE MODELS, ANIMAL; DOGS; FEMALE; FIBROSIS; GALECTIN 3; HEART; HEART FAILURE; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIUM; PRESSURE; SEVERITY OF ILLNESS INDEX; ULTRASONOGRAPHY; VENTRICULAR FUNCTION, LEFT;

EID: 84947583689     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17007     Document Type: Article

References (33)

1. Owan, T. E. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355, 251-259 (2006).
2. Vasan, R. S. et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 33, 1948-1955 (1999).
3. Paulus, W. J. et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28, 2539-2550 (2007).
4. Massie, B. M. et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359, 2456-2467 (2008).
5. Brouwers, F. P. et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 34, 1424-1431 (2013).
6. Bishu, K. et al. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J 164, 763-770 e763 (2012).
7. Edelmann, F. et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail 17, 214-223 (2015).
8. Santhanakrishnan, R. et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 14, 1338-1347 (2012).
9. Yang, R. Y., Rabinovich, G. A., Liu, F. T. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10, e17 (2008).
10. Sharma, U. C. et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110, 3121-3128 (2004).
11. de Boer, R. A. et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43, 60-68 (2011).
12. Wu, C. K. et al. Plasma levels of tumor necrosis factor-alpha and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase. Crit Care Med 39, 984-992 (2011).
13. Wu, C. K. et al. Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure. J Hypertens 27, 502-507 (2009).
14. Wu, C. K. et al. Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. Pharmacogenomics J 10, 46-53 (2010).
15. Nagueh, S. F. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22, 107-33 (2009).
16. Tseng, W. Y., Liao, T. Y., Wang, J. L. Normal systolic and diastolic functions of the left ventricle and left atrium by cine magnetic resonance imaging. J Cardiovasc Magn Reson 4, 443-457 (2002).
17. Ver Heyen, M. et al. Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+ )-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. Circ Res 89, 838-846 (2001).
18. Cheng, W. P., Wang, B. W., Chen, S. C., Chang, H., Shyu, K. G. Mechanical stretch induces the apoptosis regulator PUMA in vascular smooth muscle cells. Cardiovasc Res 93, 181-189 (2012).
19. Kundu, S., Aulchenko, Y. S., van Duijn, C. M., Janssens, A. C. PredictABEL: an R package for the assessment of risk prediction models. Eur J Epidemiol 26, 261-264 (2011).
20. Wu, C. K. et al. Connective tissue growth factor and cardiac diastolic dysfunction: human data from the Taiwan Diastolic Heart Failure Registry and molecular basis by cellular and animal models. Eur J Heart Fail 16, 163-172 (2014).
21. Frangogiannis, N. G. The immune system and cardiac repair. Pharmacol Res 58, 88-111 (2008).
22. Sasaki, S., Bao, Q., Hughes, R. C. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol 187, 481-489 (1999).
23. Beiras-Fernandez, A. et al. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation. Ann Transplant 18, 643-650 (2013).
24. Lopez, B. et al. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Fail 17, 385-392 (2015).
25. van der Velde, A. R. et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 6, 219-226 (2013).
26. de Boer, R. A., Yu, L., van Veldhuisen, D. J. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 7, 1-8 (2010).
27. Katz, A. M., Zile, M. R. New molecular mechanism in diastolic heart failure. Circulation 113, 1922-1925 (2006).
28. Wilkins, B. J. et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94, 110-118 (2004).
29. Berg, T. J. et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 22, 1186-1190 (1999).
30. Wu, C. K. et al. The Relationship Among Central Obesity, Systemic Inflammation, and Left Ventricular Diastolic Dysfunction as Determined by Structural Equation Modeling. Obesity (Silver Spring) 20, 730-737 (2012).
31. Lin, H. H. et al. Accumulation of epicardial fat rather than visceral fat is an independent risk factor for left ventricular diastolic dysfunction in patients undergoing peritoneal dialysis. Cardiovasc Diabetol 12, 127 (2013).
32. London, G. M. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 16, 85-94 (2003).
33. Lam, C. S. et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53, 1119-1126 (2009).